Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;37(1):225-233.
doi: 10.1111/jocs.15995. Epub 2021 Sep 16.

Transcatheter mitral valve therapies: State of the art

Sarah Yousef  1 , George J Arnaoutakis  2 , Hemal Gada  3 , Anson Jay Conrad Smith  3 , Saurabh Sanon  3 , Ibrahim Sultan  1   3
Affiliations
Review

Transcatheter mitral valve therapies: State of the art

Sarah Yousef et al. J Card Surg. 2022 Jan.

Abstract

Mitral regurgitation (MR) is one of the most prevalent valvular pathologies in the developed world. There continues to be a growing population of aging patients with MR who may be too high risk for surgical management. The rapid adoption and remarkable success of transcatheter aortic valve replacement (TAVR) generated enthusiasm for transcatheter mitral valve therapies; however, the complex anatomy and pathophysiology of the mitral valve confers several unique challenges for a fully percutaneous approach. Nevertheless, several devices are under development and in various phases of preclinical or clinical testing, both for transcatheter mitral valve replacement and repair. MitraClip (Abbott Vascular), which has received FDA approval, is the most established percutaneous repair strategy and has been performed in over 80,000 patients as of 2019. The following article serves as a review of the available and upcoming devices for the various etiologies of mitral valvular disease, as well as the unique challenges and potential complications of transcatheter mitral valve intervention.

Keywords: mitral regurgitation; mitral valve repair; mitral valve replacement; transcatheter mitral valve.

PubMed Disclaimer

References

REFERENCES

    1. Goode D, Dhaliwal R, Mohammadi H. Transcatheter mitral valve replacement: state of the art. Cardiovasc Eng Technol. 2020;11(3):229-253. https://doi.org/10.1007/s13239-020-00460-4
    1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. https://doi.org/10.1016/S0140-6736(06)69208-8
    1. Di Mauro M, Gallina S, D'amico MA, et al. Functional mitral regurgitation: from normal to pathological anatomy of mitral valve. Int J Cardiol. 2013;163(3):242-248. https://doi.org/10.1016/j.ijcard.2011.11.023
    1. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):e72-e227. https://doi.org/10.1161/CIR.0000000000000923
    1. Ling LH, Enriquez-Sarano M, Seward JB, et al. Early surgery in patients with mitral regurgitation due to flail leaflets: a long-term outcome study. Circulation. 1997;96(6):1819-1825. https://doi.org/10.1161/01.CIR.96.6.1819

MeSH terms

LinkOut - more resources